Skip to main content
. Author manuscript; available in PMC: 2012 May 31.
Published in final edited form as: Cell Immunol. 2011 May 31;270(2):237–250. doi: 10.1016/j.cellimm.2011.05.015

Fig 1. Identification of CRx-153, i.e., the combination of desloratadine and nortriptyline activity.

Fig 1

The ability of CRx-153, compared to its individual components was tested for the ability to inhibit inflammatory cytokine production by PBMCs. Total PBMCs were activated in vitro in the presence of PMA and ionomycin plus an increasing concentration of desloratadine, nortriptyline, or a combination of both. The level of IFN-γ (A-C) and TNF-α (D-F) were assayed via ELISA. The data is presented as the percent inhibition in the absence (A and D) or presence (B and E) of exogenous IFN-γ and TNF-α, respectively. The data is also presented in an isobologram illustrating several different dose combinations that attain the specified effect of decreasing the level of IFN-γ (C) and TNF-α (F).